

# 1 Seropositivity in blood donors and pregnant women during 9-months of 2 SARS-CoV-2 transmission in Stockholm, Sweden

3

4 Xaquín Castro Dopico<sup>1#</sup>, Sandra Muschiol<sup>2</sup>, Murray Christian<sup>1</sup>, Leo Hanke<sup>1</sup>, Daniel J.  
5 Sheward<sup>1</sup>, Nastasiya F. Grinberg<sup>3</sup>, Gordana Bogdanovic<sup>2</sup>, Gerald M. Mcinerney<sup>1</sup>, Tobias  
6 Allander<sup>1,2</sup>, Chris Wallace<sup>3,4</sup>, Ben Murrell<sup>1#</sup>, Jan Albert<sup>1,2#</sup>, Gunilla B. Karlsson Hedestam<sup>1#</sup>

7  
8 <sup>1</sup>Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden

9 <sup>2</sup>Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden

10 <sup>3</sup>Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge CB2 0AW, UK

11 <sup>4</sup>MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge CB2 0SR, United Kingdom

12 #Correspondance

13

## 14 General abstract

15 Public health strategies to contain the pandemic continue to vary markedly across the world.  
16 In Sweden, compared to most advanced economies, social restrictions have primarily relied  
17 upon voluntary adherence to a set of recommendations and strict lockdowns have not been  
18 enforced. To better understand the development of humoral immunity to SARS-CoV-2 in the  
19 Stockholm population before the start of mass vaccinations, healthy blood donors and pregnant  
20 women ( $n=4,100$ ) were sampled at random between 14<sup>th</sup> March-11<sup>th</sup> December 2020. All  
21 individuals ( $n=200$ /sampling week) were screened for anti-SARS-CoV-2 spike (S) trimer- and  
22 RBD-specific IgG responses with highly sensitive and specific ELISA assays, and the results  
23 were compared with those from historical controls ( $n=595$ ). Data were modelled using a  
24 probabilistic Bayesian framework that considered individual responses to both antigens. We  
25 found that after a steep rise at the start of the pandemic, the seroprevalence trajectory increased  
26 steadily in approach to the winter second-wave of infections, approaching 15% of all  
27 individuals surveyed by 11<sup>th</sup> December. In agreement with the high transmission rate observed  
28 in the Stockholm area, seroprevalence in this cohort of active adults increased during the 9  
29 months from the start of the outbreak, but was far from that required for herd immunity at the  
30 end of 2020.

31

## 32 Structured abstract

33 **Objectives:** As Sweden did not enforce social lockdown in response to the pandemic, it is  
34 critical to establish seropositivity to SARS-CoV-2 in healthy, active adults – here represented  
35 by blood donors and pregnant women. Random sampling was carried out in Stockholm, the  
36 country's most populous region, and the study ran from virus emergence (March 2020) until

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

37 the end of 2020, shortly prior to the first round of vaccinations, allowing for an estimate of  
38 population seropositivity in response to natural infection.

39 **Design:** In this cross-sectional prospective study, otherwise-healthy blood donors ( $n=2,100$ )  
40 and pregnant women ( $n=2,000$ ) were sampled at random for consecutive weeks (at three  
41 intervals) between 14<sup>th</sup> March and 11<sup>th</sup> December 2020. Sera from all participants and a large  
42 cohort of historical controls ( $n=595$ ) were screened for IgG responses against the SARS-CoV-  
43 2 spike (S) trimer and the receptor-binding domain (RBD). As a complement to standard  
44 approaches to analyze the data, a probabilistic Bayesian approach that assigns likelihood of  
45 past infection was used to analyze the population data. The study was carried out in accordance  
46 with Swedish Ethical Review Authority registration no. 2020-01807.

47 **Setting:** Healthy participant samples were selected from their respective pools at random  
48 through the Karolinska University Hospital.

49 **Participants:** None of the participants were symptomatic at the time of sampling and none had  
50 previously been hospitalized for COVID-19. No additional metadata was available from the  
51 samples.

52 **Results:** Blood donors and pregnant women showed a similar seroprevalence. After a steep  
53 rise at the start of the pandemic, the seroprevalence trajectory increased steadily in approach to  
54 the winter second-wave of infections, approaching 15% of all individuals surveyed by 11<sup>th</sup>  
55 December 2020. Importantly, 96% of antibody-positive healthy donors screened ( $n=56$ )  
56 developed neutralizing antibody responses at titers comparable to or higher than those observed  
57 in clinical trials of SARS-CoV-2 spike mRNA vaccination, supporting that mild infection  
58 engenders a competent B cell response.

59 **Conclusions:** In agreement with currently rising COVID-19 cases and ICU occupancy during  
60 a second winter wave of infections, these data demonstrate that the metropolitan Stockholm  
61 area was far from herd immunity nine months after the outbreak, with approximately one-in-  
62 six persons in the examined cohort seropositive for SARS-CoV-2.

63

## 64 **Introduction**

65

66 Densely populated areas – such as Stockholm county – facilitate the spread of SARS-CoV-2  
67 and evidence suggests that transmission can be curtailed by temporary restriction of leisure and  
68 business activities, and track and trace<sup>1</sup>. In contrast to the vast majority of European, American  
69 and Asian countries, Sweden has favored a strategy in which individuals are encouraged to  
70 adhere to a set of basic public health instructions, while society has remained largely open –  
71 drawing numerous criticisms. The country has reported a significantly higher burden on the  
72 healthcare system than its Scandinavian neighbors (Fig. 1A).

73

74 Enumerating past infection status over time is critical for estimating viral spread and  
75 understanding characteristics of adaptive immune responses to a new pathogen. Antibody  
76 testing is also important for optimal planning of vaccination campaigns, especially when  
77 vaccines doses are limited. Therefore, to estimate seropositivity in the capital city, we  
78 developed robust SARS-CoV-2 antibody tests and statistical methods and applied them to  
79 healthy participants in the region throughout 2020.

80

81 Blood donors and pregnant women, studied throughout, represent two good proxies for adult  
82 population health, being generally working age and mobile members of society without being  
83 enriched for individuals at especially high-risk of SARS-CoV-2 infection, such as healthcare  
84 or public transportation employees, where seroprevalence may be higher. Similarly,  
85 seroprevalence may be lower in the unexposed and elderly, and higher in children.

86

87 The data presented here follow seropositivity in across the first and second waves of infections  
88 in Stockholm, providing critical information about population immunity over time and prior to  
89 the introduction of SARS-CoV-2 vaccines.

90

91

## 92 **Materials and methods**

93

### 94 Human samples and ethical declaration

95 Anonymized samples from blood donors ( $n=100$ /sampling week) and pregnant women  
96 ( $n=100$ /sampling week) were randomly selected from their respective pools by the department  
97 of Clinical Microbiology, Karolinska University Hospital. No metadata, such as age or sex  
98 information were available for the samples in the study. Pregnant women were sampled as part  
99 of routine screening for infectious diseases during the first trimester of pregnancy. Blood  
100 donors ( $n=595$ ) collected through the same channels a year previously (Spring 2019) were  
101 randomly selected for use as assay negative controls. The use of study samples was approved  
102 by the Swedish Ethical Review Authority (registration no. 2020-01807) and no study subject  
103 was hospitalized for COVID-19 or symptomatic at sample collection. Blood donors are  
104 required to be a healthy for a minimum of two weeks before donation.

105

106 Stockholm County death and Swedish mortality data was sourced from the ECDC, EU  
107 (<https://www.ecdc.europa.eu/en/covid-19/data>) and the Swedish Public Health Agency  
108 (<https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/>), respectively, and  
109 were current with the date of publication.

110

### 111 Serum sample processing

112 Blood samples were collected by the attending clinical team and serum isolated by the  
113 department of Clinical Microbiology. Samples were anonymized, barcoded and stored at  $-20^{\circ}\text{C}$   
114 until use. Serum samples were not heat-inactivated for ELISA protocols.

115

### 116 SARS-CoV-2 antigen generation

117 The plasmid for expression of the SARS-CoV-2 prefusion-stabilized spike ectodomain with a  
118 C-terminal T4 fibrin trimerization motif was obtained from<sup>2</sup>. The plasmid was used to  
119 transiently transfect FreeStyle 293F cells using FreeStyle MAX reagent (Thermo Fisher  
120 Scientific). The ectodomain was purified from filtered supernatant on Streptactin XT resin  
121 (IBA Lifesciences), followed by size-exclusion chromatography on a Superdex 200 in 5 mM  
122 Tris pH 8, 200 mM NaCl. The RBD domain (RVQ – QFG) of SARS-CoV-2 was cloned  
123 upstream of a Sortase A recognition site (LPETG) and a 6xHIS tag, and expressed in 293F  
124 cells as described above. RBD-HIS was purified from filtered supernatant on His-Pur Ni-NTA

125 resin (Thermo Fisher Scientific), followed by size-exclusion chromatography on a Superdex  
126 200. The nucleocapsid was purchased from Sino Biological.

127

#### 128 Anti-SARS-CoV-2 ELISA

129 96-well ELISA plates (Nunc MaxiSorp) were coated with SARS-CoV-2 S trimers, RBD or  
130 nucleocapsid (100  $\mu$ l of 1 ng/ $\mu$ l) in PBS overnight at 4°C. Plates were washed six times with  
131 PBS-Tween-20 (0.05%) and blocked using PBS-5% no-fat milk. Human serum samples were  
132 thawed at room temperature, diluted (1:100 unless otherwise indicated), and incubated in  
133 blocking buffer for 1h (with vortexing) before plating. Serum samples were incubated  
134 overnight at 4°C before washing, as before. Secondary HRP-conjugated anti-human antibodies  
135 were diluted in blocking buffer and incubated with samples for 1 hour at room temperature.  
136 Plates were washed a final time before development with TMB Stabilized Chromogen  
137 (Invitrogen). The reaction was stopped using 1M sulphuric acid and optical density (OD)  
138 values were measured at 450 nm using an Asys Expert 96 ELISA reader (Biochrom Ltd.).  
139 Secondary antibodies (from Southern Biotech) and dilutions used: goat anti-human IgG (2014-  
140 05) at 1:10,000. All assays were developed for their fixed time and negative control samples  
141 were run alongside test samples in all assays. Raw 450nm optical density data were log  
142 transformed for statistical analyses.

143

#### 144 *In vitro* virus neutralisation assay

145 Pseudotyped viruses were generated by the co-transfection of HEK293T cells with plasmids  
146 encoding the SARS-CoV-2 spike protein harboring an 18 amino acid truncation of the  
147 cytoplasmic tail<sup>2</sup>; a plasmid encoding firefly luciferase; a lentiviral packaging plasmid  
148 (Addgene 8455) using Lipofectamine 3000 (Invitrogen). Media was changed 12-16 hours post-  
149 transfection and pseudotyped viruses harvested at 48- and 72-hours, filtered through a 0.45  $\mu$ m  
150 filter and stored at -80°C until use. Pseudotyped neutralisation assays were adapted from  
151 protocols validated to characterize the neutralization of HIV, but with the use of HEK293T-  
152 ACE2 cells. Briefly, pseudotyped viruses sufficient to generate ~100,000 RLU were incubated  
153 with serial dilutions of heat-inactivated serum for 60 min at 37°C. Approximately 15,000  
154 HEK293T-ACE2 cells were then added to each well and the plates incubated at 37°C for 48  
155 hours. Luminescence was measured using Bright-Glo (Promega) according to the  
156 manufacturer's instructions on a GM-2000 luminometer (Promega) with an integration time of  
157 0.3s. The limit of detection was at a 1:45 serum dilution.

158

## 159 Probabilistic seroprevalence estimations

160 Prior to analysis, each sample OD was standardized by dividing by the mean OD of “no sample  
161 controls” on that plate or other plates run on the same day. This resulted in more similar  
162 distributions for 2019 blood donor samples with 2020 blood donors and pregnant volunteers.  
163 Our Bayesian approach is presented in detail in Christian *et al*<sup>3</sup>. Briefly, we used a logistic  
164 regression over anti-RBD and -S training data (from  $n=595$  historical blood donor controls and  
165  $n=138$  SARS-CoV-2 PCR+ individuals across the clinical spectrum) to model the relationship  
166 between the ELISA measurements and the probability that a sample is antibody-positive. We  
167 adjusted for the training data class proportions and used these adjusted probabilities to inform  
168 the seroprevalence estimates for each time point. Given that the population seroprevalence  
169 cannot increase dramatically from one week to the next, we constructed a prior over  
170 seroprevalence trajectories using a transformed Gaussian Process, and combined this with the  
171 individual class-balance adjusted infection probabilities for each donor to infer the posterior  
172 distribution over seroprevalence trajectories. We validated our Bayesian approach by  
173 comparing the output with that of more established probabilistic algorithms (support vector  
174 machines and linear discriminant analysis) that we have previously developed for ELISA  
175 measurements<sup>4</sup>, finding strong congruency between the approaches.

## 176 177 **Results**

178  
179 Blood donor and pregnant women serum samples ( $n=100$  of each per sampling week) were  
180 selected at random from their respective pools and the IgG response against SARS-CoV-2 S  
181 glycoprotein trimers and the smaller RBD subunit was measured in all sera using established  
182 ELISA assays<sup>4</sup> (Fig. 1B-E). Test samples were run alongside historical (negative) control sera  
183 ( $n=595$  blood donors from spring 2019) throughout the study.

184  
185 Using conventional 3 or 6 standard deviations (SD) from the mean of negative control sera as  
186 assay cut-offs for positivity, and simple linear regression, between 17-21% and 14-19% of  
187 individuals were IgG-positive against spike or the RBD, respectively, at the last sampling point  
188 (11<sup>th</sup> December) (Fig. 1F).

189  
190 However, the many measurements between the 3 and 6 SD cut-offs for both or a single antigen  
191 highlight the problem of assigning case to low values. Therefore, to provide an accurate  
192 seropositivity estimates for this metric and to model population-level changes over time, we

193 developed and validated a cut-off-independent, probabilistic Bayesian framework that models  
194 the log odds a sample is antibody-positive based on responses in training data; in this case  
195 SARS-CoV-2 PCR+ COVID-19 patients across the clinical spectrum that we have extensively  
196 characterized<sup>3,4</sup>. The correct classification of low titers is important, since a number of cases  
197 that have experienced asymptomatic or mild infection generate antibody titers closer to the  
198 assay boundary, and antibody levels decline with time in all seropositive individuals, meaning  
199 that incorrect classification can skew seroprevalence estimates<sup>4-7</sup>.

200

201 Using this more quantitative approach that considers the wide range of responses present in the  
202 population and shares information between sampling weeks, we found seropositivity to  
203 increase sharply at the start of the pandemic (Fig. 1G). By the time COVID-19 deaths in the  
204 country were at very low levels during August, the seroprevalence trajectory increased at a  
205 slower rate approaching to the winter second wave (Fig. 1A and G), in agreement with  
206 continued viral spread in the Stockholm population, and consistent with persistent antibody  
207 responses over a 9-month period.

208

209 By week 50 (11<sup>th</sup> December), our probabilistic approach identified 14.8% (95% Bayesian CI  
210 [12.2-18.0]) of the cohort to have been previously infected (Supp. Table 1). We validated the  
211 estimates from our Bayesian approach with an equal-weighted (cut-off-independent) learner  
212 from the output of support vector machines and linear discriminant analysis that we previously  
213 optimized for ELISA measurements (Fig. 1G)<sup>4</sup>, which showed highly consistent results.

214

215 Importantly, 96% of antibody-positive blood donors and pregnant women randomly sub-  
216 sampled from the entire cohort ( $n=56$ ) had virus neutralizing responses in their sera ( $ID_{50}=600$ ;  
217 95% CI [357 – 1,010] and  $ID_{50}=350$ ; 95% CI [228 - 538], respectively, Fig. 1H-I), with titers  
218 comparable to those engendered by recently-approved COVID-19 mRNA vaccines that were  
219 shown to be protective in clinical phase 3 trials<sup>8,9</sup>. These observations support that  
220 asymptomatic/mild infection generates an antibody response that provides a first line of  
221 defense against potential re-exposures<sup>10</sup>, although inter-individual heterogeneity will have a  
222 role in outcomes<sup>11-13</sup>.

223

224



## 225 Discussion

226

227 To characterize immunological responses to SARS-CoV-2 and safeguard public health, it is  
228 critical to monitor the level of population immunity after natural infection<sup>14</sup>, especially in  
229 settings with different public health measures – allowing for concurrent and retroactive  
230 evaluation of different strategies. As Sweden has taken a unique public health approach to  
231 mitigate the effects of the virus, data from the country provide an important contrast to  
232 comparable settings and may help inform future pandemic management.

233

234 Serology is amenable to studies of large cohorts and is the *gold standard* for determining  
235 previous exposure to pathogens. Importantly, increasing evidence suggests that most persons  
236 infected with SARS-CoV-2 develop virus-specific antibodies, including following mild or  
237 asymptomatic infections<sup>4,15,16</sup>. Studies have highlighted the protective role B cells play in  
238 controlling SARS-CoV-2 infection in humans<sup>10</sup> and animal models<sup>17,18</sup>, while potent  
239 neutralizing antibodies were rapidly isolated from infected donor samples<sup>19–21</sup>. Critical future  
240 research is required to determine the duration of B cell memory in those infected, as well as  
241 following vaccination. Early results show that infected individuals can maintain a detectable  
242 virus-specific B cell response for at least eight months<sup>20,22</sup>, which together with the steadily  
243 increasing seropositivity observed in the study (and in NYC<sup>23</sup>), help allay early fears that  
244 immunity waned in the short-term; although individuals with mild infection can have titers  
245 close to the assay boundary that may decline from peak responses at different rates between  
246 individuals. Neutralizing titers in our study samples were comparable to those engendered by  
247 the first mRNA vaccines, supporting that natural infection generates immunological memory.  
248 Given these observations, antibody testing should be used for optimal coordination of vaccine  
249 interventions, especially in the near future when vaccine doses are expected to be limited.

250

251 Epidemiologically, the data presented here indicate that nine months after viral emergence in  
252 Stockholm, Sweden – and in the midst of a winter second wave – approximately one-in-six  
253 active adults (represented by blood donors and pregnant women) have been infected with the  
254 virus. Although this is a considerable number, which is associated with a significant public  
255 health burden<sup>24</sup>, this proportion remains far from that required for herd immunity. This situation  
256 in Stockholm is similar to that observed in New York City, USA, where despite high rates of  
257 infection and mortality<sup>25</sup>, herd immunity was not attained within six months of the outbreak,  
258 reaching *ca.* 20% of the general population<sup>23</sup>. Compared to other European regions, our study



259 supports that Stockholm has fared worse in terms of infections (following the first wave) than  
260 the majority of study locations<sup>26–28</sup>, with the exception of Lombardy, Italy (23% seropositivity,  
261 an early European center of infection)<sup>29</sup>, and comparable to London, UK (13%)<sup>30</sup> and Geneva,  
262 Switzerland (11%)<sup>31</sup>. However, direct comparisons between sites are complicated by  
263 differences in the demographics of the study subjects as well as the sensitivity of the assay used  
264 for antibody detection<sup>32</sup>. Longitudinal studies over longer timescales (first, second and future  
265 waves), using robust antibody tests and different cohorts are urgently needed for improved  
266 comparisons and understanding COVID-19.

267

268 Together, the results presented here highlight the continued need for measures to curtail virus  
269 dissemination and protect the most vulnerable in society. Understanding seroprevalence  
270 changes in the population (and individuals) over time - including following the introduction of  
271 vaccines - is of fundamental importance for informing public health approaches.

272

### 273 **Author contributions**

274

275 GKH and XCD designed the study, analyzed the data and wrote the manuscript with input from  
276 co-authors. JA, TA, SM and GB provided the study samples. XCD generated the ELISA data.  
277 LH, DJS, GM and BM generated SARS-CoV-2 antigens and pseudotyped viruses. DJS  
278 performed the neutralization assay. MC, CW, N.F.G, and BM carried out statistical analyses.  
279 MC and BM developed the Bayesian framework.

280

### 281 **Acknowledgments**

282

283 We would like to thank the study participants and attending clinical teams. Funding for this  
284 work was provided by a Distinguished Professor grant from the Swedish Research Council  
285 (agreement 2017-00968) and the National Institutes of Health, USA (agreement 400  
286 SUM1A44462-02) awarded to GKH. CW received funding from the Wellcome Trust  
287 (WT107881) and Medical Research Council, UK (MC\_UP\_1302/5). For the purpose of Open  
288 Access, the author has applied a CC BY public copyright licence to any Author Accepted  
289 Manuscript version arising from this submission. We thank Joanna Rorbach, for critical reading  
290 of the manuscript.

291

### 292 **Conflict of interest**

293

294 The study authors declare no competing interests related to the work.

295

## 296 **Data and code availability statement**

297

298 Data generated as part of the study, along with custom code for statistical analyses, is openly  
299 available via our GitHub repositories: [https://github.com/MurrellGroup/  
300 DiscriminativeSeroprevalence/](https://github.com/MurrellGroup/DiscriminativeSeroprevalence/) and <https://github.com/chr1swallace/seroprevalence-paper>.

301


## 302 **References**

303

- 304 1. Nicola, M. *et al.* Health policy and leadership models during the COVID-19 pandemic:  
305 A review. *International Journal of Surgery* (2020) doi:10.1016/j.ijssu.2020.07.026.
- 306 2. Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion  
307 conformation. *Science* (80-. ). (2020) doi:10.1126/science.aax0902.
- 308 3. Christian, M. & Murrell, B. Discriminative Bayesian Serology: Counting Without  
309 Cutoffs. *BioRxiv* (2020).
- 310 4. Dopico, X. *et al.* A probability-based approach for identifying low-titer antibody  
311 responses against SARS-CoV-2. *Medrxiv* (2020).
- 312 5. Shrock, E. *et al.* Viral epitope profiling of COVID-19 patients reveals cross-reactivity  
313 and correlates of severity. *Science* (80-. ). (2020) doi:10.1126/science.abd4250.
- 314 6. Altman, D. G. & Royston, P. The cost of dichotomising continuous variables. *British*  
315 *Medical Journal* (2006) doi:10.1136/bmj.332.7549.1080.
- 316 7. Cervia, C. *et al.* Systemic and mucosal antibody responses specific to SARS-CoV-2  
317 during mild versus severe COVID-19. *J. Allergy Clin. Immunol.* (2020)  
318 doi:10.1016/j.jaci.2020.10.040.
- 319 8. Mulligan, M. J. *et al.* Phase I/II study of COVID-19 RNA vaccine BNT162b1 in  
320 adults. *Nature* (2020) doi:10.1038/s41586-020-2639-4.
- 321 9. Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 — Preliminary Report.  
322 *N. Engl. J. Med.* (2020) doi:10.1056/nejmoa2022483.
- 323 10. Addetia, A. *et al.* Neutralizing antibodies correlate with protection from SARS-CoV-2  
324 in humans during a fishery vessel outbreak with a high attack rate. *J. Clin. Microbiol.*  
325 (2020) doi:10.1128/JCM.02107-20.
- 326 11. Jonsson, S. *et al.* Identification of sequence variants influencing immunoglobulin  
327 levels. *Nat. Genet.* (2017) doi:10.1038/ng.3897.

- 328 12. Brodin, P. & Davis, M. M. Human immune system variation. *Nature Reviews*  
329 *Immunology* (2017) doi:10.1038/nri.2016.125.
- 330 13. Dopico, X. C. *et al.* Widespread seasonal gene expression reveals annual differences in  
331 human immunity and physiology. *Nat. Commun.* **6**, 7000 (2015).
- 332 14. Winter, A. K. & Hegde, S. T. The important role of serology for COVID-19 control.  
333 *The Lancet Infectious Diseases* (2020) doi:10.1016/S1473-3099(20)30322-4.
- 334 15. Gudbjartsson, D. F. *et al.* Spread of SARS-CoV-2 in the Icelandic Population. *N. Engl.*  
335 *J. Med.* (2020) doi:10.1056/nejmoa2006100.
- 336 16. Long, Q. X. *et al.* Clinical and immunological assessment of asymptomatic SARS-  
337 CoV-2 infections. *Nat. Med.* (2020) doi:10.1038/s41591-020-0965-6.
- 338 17. Chandrashekar, A. *et al.* SARS-CoV-2 infection protects against rechallenge in rhesus  
339 macaques. *Science* (80-. ). (2020) doi:10.1126/science.abc4776.
- 340 18. Deng, W. *et al.* Primary exposure to SARS-CoV-2 protects against reinfection in  
341 rhesus macaques. *Science* (80-. ). (2020) doi:10.1126/science.abc5343.
- 342 19. Robbiani, D. F. *et al.* Convergent Antibody Responses to SARS-CoV-2 Infection in  
343 Convalescent Individuals. *Nature* (2020) doi:10.1101/2020.05.13.092619.
- 344 20. Wajnberg, A. *et al.* Robust neutralizing antibodies to SARS-CoV-2 infection persist  
345 for months. *Science* (80-. ). (2020) doi:10.1126/science.abd7728.
- 346 21. Ju, B. *et al.* Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*  
347 (2020) doi:10.1038/s41586-020-2380-z.
- 348 22. Dan, J. M. *et al.* Immunological memory to SARS-CoV-2 assessed for greater than  
349 eight months after infection. *bioRxiv* (2020).
- 350 23. Stadlbauer, D. *et al.* Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New  
351 York City. *Nature* (2020) doi:10.1038/s41586-020-2912-6.
- 352 24. Gémes, K. *et al.* Burden and prevalence of prognostic factors for severe COVID-19 in  
353 Sweden. *Eur. J. Epidemiol.* (2020) doi:10.1007/s10654-020-00646-z.
- 354 25. Yang, W. *et al.* Estimating the infection-fatality risk of SARS-CoV-2 in New York  
355 City during the spring 2020 pandemic wave: a model-based analysis. *Lancet Infect.*  
356 *Dis.* (2020) doi:10.1016/S1473-3099(20)30769-6.
- 357 26. Rostami, A. *et al.* SARS-CoV-2 seroprevalence worldwide: a systematic review and  
358 meta-analysis. *Clinical Microbiology and Infection* (2020)  
359 doi:10.1016/j.cmi.2020.10.020.
- 360 27. Pollán, M. *et al.* Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide,  
361 population-based seroepidemiological study. *Lancet* (2020) doi:10.1016/S0140-

- 362 6736(20)31483-5.
- 363 28. Fischer, B., Knabbe, C. & Vollmer, T. SARS-CoV-2 IgG seroprevalence in blood  
364 donors located in three different federal states, Germany, March to June 2020.  
365 *Eurosurveillance* (2020) doi:10.2807/1560-7917.ES.2020.25.28.2001285.
- 366 29. Percivalle, E. *et al.* Prevalence of SARS-CoV-2 specific neutralising antibodies in  
367 blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020.  
368 *Eurosurveillance* (2020) doi:10.2807/1560-7917.ES.2020.25.24.2001031.
- 369 30. Ward, H. *et al.* Antibody prevalence for SARS-CoV-2 in England following first peak  
370 of the pandemic: REACT2 study in 100,000 adults. *medRxiv* (2020).
- 371 31. Stringhini, S. *et al.* Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva,  
372 Switzerland (SEROCoV-POP): a population-based study. *Lancet* (2020)  
373 doi:10.1016/S0140-6736(20)31304-0.
- 374 32. GeurtsvanKessel, C. H. *et al.* Towards the next phase: evaluation of serological assays  
375 for diagnostics and exposure assessment. *Nat Comms* **doi: 10.10**, (2020).
- 376
- 377



**Figure 1: SARS-CoV-2 seropositivity estimates in Stockholm: March-December 2020.** (A) Population-adjusted COVID-19 deaths for selected countries during the pandemic. (B) Anti-S IgG responses in blood donors (BD), pregnant women (PW) and  $n=595$  historical control sera. 100 BD and 100 PW samples were analyzed per sampling week. Conventional 3 and 6 SD assay cut-offs are shown as dashed and solid lines, respectively. (C) Spike seropositivity in BD and PW according to 3 and 6 SD cut-offs. (D) Anti-RBD IgG responses in blood donors (BD), pregnant women (PW) and  $n=595$  historical control sera. Conventional 3 and 6 SD assay cut-offs are shown as dashed and solid lines, respectively. (E) RBD seropositivity in BD and PW according to 3 and 6 SD cut-offs. (F) Seropositivity estimates in BD and PW combined according to 3 and 6 SD cut-offs. Simple linear regression was applied to each estimate. (G) Cut-off-independent Bayesian modelling of population seropositivity. A frequentist, equal-weighted ensemble learner from the output of support vector machines and linear discriminant analysis was used to validate the Bayesian framework. (H) *In vitro* pseudotyped virus neutralizing titers in a subset of antibody-positive BD and PW. Bars represent the geometric mean. (I) Binding and neutralization - for samples in (H) - are highly correlated.